SAB BIOTHERAPEUTICS, INC. (SABS) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
13/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseSABS / S&P 1.83% / 15.20% |
LoseSABS / S&P SABS unavailable / 15.00% |
LoseSABS / S&P -67.50% / 50.40% |
| 2026-Q11/3 |
WinSABS / S&P 2.41% / -4.33% |
LoseSABS / S&P SABS unavailable / 11.30% |
LoseSABS / S&P -42.97% / 27.70% |
| 2025-Q41/3 |
WinSABS / S&P 86.07% / 2.65% |
LoseSABS / S&P SABS unavailable / 9.00% |
LoseSABS / S&P -36.96% / 13.40% |
| 2025-Q31/3 |
WinSABS / S&P 14.53% / 8.12% |
LoseSABS / S&P SABS unavailable / 4.61% |
LoseSABS / S&P -50.95% / 13.45% |
| 2025-Q21/3 |
WinSABS / S&P 29.04% / 10.94% |
LoseSABS / S&P SABS unavailable / 4.83% |
LoseSABS / S&P -34.96% / 10.63% |
| 2025-Q10/3 |
LoseSABS / S&P -64.15% / -4.27% |
LoseSABS / S&P SABS unavailable / 4.98% |
LoseSABS / S&P -44.94% / 10.57% |
| 2024-Q41/3 |
WinSABS / S&P 40.52% / 2.41% |
LoseSABS / S&P SABS unavailable / 5.25% |
LoseSABS / S&P -51.83% / 6.15% |
| 2024-Q30/3 |
LoseSABS / S&P -12.90% / 5.89% |
LoseSABS / S&P SABS unavailable / 5.89% |
LoseSABS / S&P -19.75% / 6.11% |
| 2024-Q20/3 |
LoseSABS / S&P -31.72% / 4.28% |
LoseSABS / S&P -56.68% / 5.38% |
LoseSABS / S&P -12.64% / 5.12% |
| 2024-Q11/3 |
LoseSABS / S&P -34.01% / 10.56% |
LoseSABS / S&P -79.48% / 5.71% |
WinSABS / S&P 16.06% / 5.59% |
| 2023-Q41/3 |
LoseSABS / S&P 9.21% / 11.69% |
LoseSABS / S&P -90.63% / 6.81% |
WinSABS / S&P 77.26% / 7.78% |
| 2023-Q31/3 |
LoseSABS / S&P -24.10% / -3.27% |
LoseSABS / S&P -87.52% / 7.52% |
WinSABS / S&P 1089.39% / -5.03% |
| 2023-Q22/3 |
WinSABS / S&P 88.64% / 8.74% |
LoseSABS / S&P -85.38% / 9.50% |
WinSABS / S&P 966.67% / -8.57% |
| 2023-Q11/3 |
LoseSABS / S&P -25.42% / 7.50% |
LoseSABS / S&P -77.25% / 10.77% |
WinSABS / S&P 777.27% / -15.69% |
| 2022-Q41/3 |
LoseSABS / S&P -15.83% / 7.56% |
LoseSABS / S&P -60.73% / 11.88% |
WinSABS / S&P 584.13% / -17.99% |
| 2022-Q30/3 |
LoseSABS / S&P -51.66% / -4.88% |
LoseSABS / S&P SABS unavailable / 13.47% |
LoseSABS / S&P SABS unavailable / -1.41% |
| 2022-Q20/3 |
LoseSABS / S&P -61.44% / -16.10% |
LoseSABS / S&P SABS unavailable / 13.71% |
LoseSABS / S&P SABS unavailable / 11.04% |
| 2022-Q10/3 |
LoseSABS / S&P -51.86% / -4.60% |
LoseSABS / S&P SABS unavailable / 15.97% |
LoseSABS / S&P SABS unavailable / 42.23% |
| 2021-Q40/3 |
LoseSABS / S&P -22.52% / 11.03% |
LoseSABS / S&P SABS unavailable / 15.00% |
LoseSABS / S&P SABS unavailable / 96.40% |
| 2021-Q31/3 |
WinSABS / S&P 1.17% / 0.58% |
LoseSABS / S&P SABS unavailable / 10.77% |
LoseSABS / S&P SABS unavailable / 69.42% |
| 2021-Q20/3 |
LoseSABS / S&P 1.46% / 8.55% |
LoseSABS / S&P SABS unavailable / 6.58% |
LoseSABS / S&P SABS unavailable / 51.81% |
| 2021-Q10/3 |
LoseSABS / S&P SABS unavailable / 6.17% |
LoseSABS / S&P SABS unavailable / -1.06% |
LoseSABS / S&P SABS unavailable / 7.39% |
| 2020-Q40/3 |
LoseSABS / S&P SABS unavailable / 12.15% |
LoseSABS / S&P SABS unavailable / -3.72% |
LoseSABS / S&P SABS unavailable / -33.42% |
| 2020-Q30/3 |
LoseSABS / S&P SABS unavailable / 8.93% |
LoseSABS / S&P SABS unavailable / -2.04% |
LoseSABS / S&P SABS unavailable / -27.10% |
| 2020-Q20/3 |
LoseSABS / S&P SABS unavailable / 20.54% |
LoseSABS / S&P SABS unavailable / -0.46% |
LoseSABS / S&P SABS unavailable / -27.11% |
| 2020-Q10/3 |
LoseSABS / S&P SABS unavailable / -19.60% |
LoseSABS / S&P SABS unavailable / 3.47% |
LoseSABS / S&P SABS unavailable / -14.75% |
| 2019-Q40/3 |
LoseSABS / S&P SABS unavailable / 9.07% |
LoseSABS / S&P SABS unavailable / 5.36% |
LoseSABS / S&P SABS unavailable / 2.99% |
| 2019-Q30/3 |
LoseSABS / S&P SABS unavailable / 1.70% |
LoseSABS / S&P SABS unavailable / 5.02% |
LoseSABS / S&P SABS unavailable / 0.21% |
| 2019-Q20/3 |
LoseSABS / S&P SABS unavailable / 4.30% |
LoseSABS / S&P SABS unavailable / 6.64% |
LoseSABS / S&P SABS unavailable / 8.65% |
| 2019-Q10/3 |
LoseSABS / S&P SABS unavailable / 13.65% |
LoseSABS / S&P SABS unavailable / 8.12% |
LoseSABS / S&P SABS unavailable / 14.29% |
| 2018-Q40/3 |
LoseSABS / S&P SABS unavailable / -13.52% |
LoseSABS / S&P SABS unavailable / 9.05% |
LoseSABS / S&P SABS unavailable / 18.23% |
| 2018-Q30/3 |
LoseSABS / S&P SABS unavailable / 7.71% |
LoseSABS / S&P SABS unavailable / 10.21% |
LoseSABS / S&P SABS unavailable / 19.06% |
| 2018-Q20/3 |
LoseSABS / S&P SABS unavailable / 3.43% |
LoseSABS / S&P SABS unavailable / 9.03% |
LoseSABS / S&P SABS unavailable / 14.46% |
| 2018-Q10/3 |
LoseSABS / S&P SABS unavailable / -0.76% |
LoseSABS / S&P SABS unavailable / 7.68% |
LoseSABS / S&P SABS unavailable / 12.46% |
| 2017-Q40/3 |
LoseSABS / S&P SABS unavailable / 6.64% |
LoseSABS / S&P SABS unavailable / 7.03% |
LoseSABS / S&P SABS unavailable / 13.82% |
| 2017-Q30/3 |
LoseSABS / S&P SABS unavailable / 4.48% |
LoseSABS / S&P SABS unavailable / 5.68% |
LoseSABS / S&P SABS unavailable / 17.57% |
| 2017-Q20/3 |
LoseSABS / S&P SABS unavailable / 3.09% |
LoseSABS / S&P SABS unavailable / 4.83% |
LoseSABS / S&P SABS unavailable / 17.74% |
| 2017-Q10/3 |
LoseSABS / S&P SABS unavailable / 6.07% |
LoseSABS / S&P SABS unavailable / 3.67% |
LoseSABS / S&P SABS unavailable / 13.32% |
| 2016-Q40/3 |
LoseSABS / S&P SABS unavailable / 3.82% |
LoseSABS / S&P SABS unavailable / 2.09% |
LoseSABS / S&P SABS unavailable / 7.05% |
| 2016-Q30/3 |
LoseSABS / S&P SABS unavailable / 3.85% |
LoseSABS / S&P SABS unavailable / 0.20% |
LoseSABS / S&P SABS unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | SABS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 88.94% | 20.78% |
| Annualized return | 88.94% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | SABS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -96.06% | 83.14% |
| Annualized return | -47.62% | 12.86% |
10Y · 2021-02-09 to 2026-08-27
| Metric | SABS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -96.13% | 319.30% |
| Annualized return | -27.76% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |